Loss of androgen receptor after neoadjuvant anti-HER2 therapy in patients with locally advanced HER2-positive breast cancer

被引：0
|
作者：
Espinosa Fernandez, Jose Rodrigo [1 ]
Sahin, Aysegul A. [2 ]
Hess, Kenneth R. [2 ]
Ramirez Medina, Raul Gerardo [1 ]
Cabrera Galeana, Paula Anel [1 ]
Espana Ferrufino, Alejandro Javier [1 ]
Esparza Arias, Nereida [1 ]
Bargallo Rocha, Juan Enrique [1 ]
Garcia Gordillo, Jose Antonio [1 ]
Lopez Muniz, Gerardo Emmanuel [1 ]
Ueno, Naoto T. [2 ]
机构：
[1] Natl Canc Inst INCAN Mexico City, Mexico City, DF, Mexico
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P4-10-22
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-10-22
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Loss of HER2 expression in HER2-positive breast cancer patients after neoadjuvant therapy
    Sang, Yuting
    Wu, Jiong
    Yang, Benlong
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [2] Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
    Kutlu, Yasin
    Cekin, Ruhper
    Aydin, Sabin Goktas
    Shbair, Abdallah T. M.
    Bilici, Ahmet
    Arici, Serdar
    Oven, Bala Basak
    Acikgoz, Ozgur
    Ozcan, Erkan
    Olmez, Omer Fatih
    Cakir, Asli
    Seker, Mesut
    [J]. CURRENT PROBLEMS IN CANCER, 2024, 50
  • [3] Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
    Guarneri, V.
    Dieci, M. V.
    Barbieri, E.
    Piacentini, F.
    Omarini, C.
    Ficarra, G.
    Bettelli, S.
    Conte, P. F.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (12) : 2990 - 2994
  • [4] Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer
    Yu, Anthony F.
    Singh, Jasmeet C.
    Wang, Rui
    Liu, Jennifer E.
    Eaton, Anne
    Oeffinger, Kevin C.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    [J]. ONCOLOGIST, 2017, 22 (06): : 642 - 647
  • [5] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    [J]. CANCER CONTROL, 2023, 30
  • [6] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    [J]. CANCER CONTROL, 2022, 29
  • [7] Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer
    Guarneri, Valentina
    Barbieri, Elena
    Piacentini, Federico
    Dieci, Maria Vittoria
    Omarini, Claudia
    Ficarra, Guido
    Bettelli, Stefania Raffaella
    Conte, Pier Franco
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
    Xie, Yifan
    Wu, Siyu
    Zhang, Ying
    Li, Jianwei
    Mo, Miao
    Shao, Zhimin
    Liu, Guangyu
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] Anti-HER2 therapy for HER2-positive metastatic breast cancer: regimens and treatment outcomes
    Watanabe, Kenichi
    Hagio, Kanako
    Baba, Motoi
    Ikarashi, Mayuko
    Sato, Masako
    Tomioka, Nobumoto
    Takahashi, Masato
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [10] Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis
    Debiasi, Marcio
    Polanczyk, Carisi A.
    Ziegelmann, Patricia
    Barrios, Carlos
    Cao, Hongyuan
    Dignam, James J.
    Goss, Paul
    Bychkovsky, Brittany
    Finkelstein, Dianne M.
    Guindalini, Rodrigo S.
    Filho, Paulo
    Albuquerque, Caroline
    Reinert, Tomas
    de Azambuja, Evandro
    Olopade, Olufunmilayo
    [J]. FRONTIERS IN ONCOLOGY, 2018, 8
12345